According to CACLP, the total amount of repurchase of the 16 IVD listed companies that will implement buybacks in 2023 will exceed 336.1 billion yuan, accounting for 37% of the total annual repurchase of 9.2 billion yuan (wind data statistics) of 154 biomedical sectors, is the backbone of the repurchase army in the biomedical industry. Among them, Jiu'an Medical repurchased about 1 billion yuan during the yearHuada Manufacturing and Lepu Medical followed, with a repurchase amount of 500 million yuan respectivelyWantai Biotechnology and Kehua Biotechnology repurchased 400 million yuan and 200 million yuan respectivelyThe annual repurchase amount of Jinyu Medical, Sinocare Biotechnology and Biotest Biotechnology all exceeded 100 million yuan.
According to the public data of A-shares, IVD listed companies mainly carry out repurchases through their own funds, including directional repurchase and centralized bidding transactions, and the purpose of repurchase involves the cancellation of equity incentives, the implementation of equity incentives or employee stock ownership plans, market value management, etc.
Detailed report of the repurchase of 16 IVD listed companies
*According to the announcement of listed companies, if there is any omission, please add it in the message area below.
According to the purpose of the repurchase disclosed in the repurchase announcement, Jiu'an Medical said that the repurchased shares are mainly used to maintain the company's value and shareholders' equity, and the rest is used for the employee stock ownership plan, aiming to effectively promote the company's long-term development. Based on their confidence in the company's future development and the recognition of the company's value, MGI and other enterprises safeguard the interests of investors, enhance investors' confidence in the company's investment, and promote the company's stable and healthy development, effectively combine the interests of shareholders, the company and the personal interests of employees, and use part of the repurchased shares for employee stock ownership plans or equity incentives.
On December 15, the China Securities Regulatory Commission revised and issued the "Rules for Share Repurchase of Listed Companies", aiming to promote listed companies to attach importance to repurchase, implement repurchase, standardize repurchase, and actively safeguard the company's value and shareholders' rights and interests by improving the convenience of the repurchase system and improving the repurchase constraint mechanism. Industry insiders believe that the above measures optimize the share repurchase policy of listed companies, further stimulate the company's enthusiasm for repurchase, and the share repurchase efforts of A-share listed companies are expected to continue to increase.